This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biodexa Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

Biodexa Pharmaceuticals has a total shareholder equity of £7.5M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £9.7M and £2.2M respectively.

주요 정보

부채 비율

UK£0

부채

이자 보상 비율	n/a
현금	UK£6.42m
주식	UK£7.49m
총 부채	UK£2.19m
총 자산	UK£9.68m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: 5MP0's short term assets (£8.7M) exceed its short term liabilities (£1.6M).

장기 부채: 5MP0's short term assets (£8.7M) exceed its long term liabilities (£546.0K).

부채 대 자본 내역 및 분석

부채 수준: 5MP0 is debt free.

부채 감소: 5MP0 has no debt compared to 5 years ago when its debt to equity ratio was 4.8%.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: Insufficient data to determine if 5MP0 has enough cash runway based on its current free cash flow.

예측 현금 활주로: Insufficient data to determine if 5MP0 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

This company listing is no longer active

Biodexa Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Recent updates

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Full year 2021 earnings released: UK£0.07 loss per share (vs UK£0.52 loss in FY 2020)

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

New 90-day high: €0.45

New 90-day high: €0.34

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

New 90-day low: €0.25

New 90-day low: €0.26

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

First half earnings released

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

New 90-day high - €0.94

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기